Lyra Therapeutics (Nasdaq:LYRA) announced today that it appointed Dr. Richard Nieman as its new chief medical officer (CMO).
Nieman’s appointment as CMO of Lyra, which develops the XTreo — a platform for enabling precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — will be made effective on July 11, 2022.
“We’re pleased to welcome Dr. Nieman as our chief medical officer,” Lyra CEO Maria Palasis said in a news release. “Dr. Nieman joins the Lyra team at a critical time with our lead candidate LYR-210 in pivotal Phase 3 trials. Having successfully developed and launched numerous innovative medicines for patients and their families during the course of his career, his experience building and leading medical organizations will be invaluable as we work to bring new treatments to patients with chronic rhinosinusitis (CRS).”
Nieman joins Watertown, Massachusetts-based Lyra with more than 25 years of experience in drug development and medical affairs. He previously served as SVP and worldwide medical head of immunology at Bristol Myers Squibb, head of R&D China at BMS, global medical officer and head of medical at Teva and head of Asia Pacific medical at Bayer.
Having garnered extensive experience in the U.S., Nieman has spent significant time working in China, the rest of Asia and Europe. His background includes bringing medicines to market in the U.S. and Europe, including Cinquair in asthma, Copaxone 40 mg 3x/week in multiple sclerosis, Austedo in movement disorders, Ajovy in migraine and Xarelto in thrombosis and stroke prevention.
“I’m thrilled to be taking on this role during such an exciting time in Lyra’s growth and evolution with late-stage clinical programs,” Nieman said. “There is a significant need for effective treatments for patients suffering with CRS, and I look forward to working with the Lyra team to build on the compelling data to date and contributing my abilities and experience as the company drives towards commercialization.”